Edgemont Pharamaceuticals Receives $5M Loan from Oxford Finance

logo-edgemontEdgemont Pharamaceuticals, LLC, an Austin, Texas-based developer of drug formulations and therapies in the field of psychiatry, closed a $5m expansion to an existing $10m senior secured term loan agreement with Oxford Finance LLC.

The additional funds will be used primarily for working and growth capital.

Led by Douglas A. Saltel, chief executive officer, Edgemont Pharmaceuticals is a specialty pharmaceutical company focused on psychiatry.
The company has two FDA approved antidepressant products commercialized in the US and a Phase III product candidate being developed for Generalized Anxiety Disorder.



Join the discussion